Oncology Liquid Biopsy (LBx) Market Report 2022 - 2027

Liquid biopsies (LBx), which, to-date, have been used largely for genomic profiling and therapy selection, are finding new applications throughout the patient journey and within pharma research.  Less invasive and faster to process than tissue samples, liquid biopsies provide both clinicians and researchers with an effective tool for biomarker testing, especially serially.  Liquid biopsies can also be used to detect the earliest signs of cancer, providing an alternative to existing screening methods, or a new option for many cancers without any screening protocols at all.  The increasing clinical validation of liquid biopsies, emerging applications, and technological improvements are expected to drive significant growth of the LBx market in the near-midterm.  Even so, the markets for early cancer detection and MRD / monitoring will still be immature by the end of the forecast window for this report, with significant growth in the decades ahead.

This second-edition of DeciBio’s liquid biopsy report takes a completely updated and comprehensive look at the LBx landscape.  Informed by a combination of primary (36 interviews with oncology and early cancer detection stakeholders) and secondary research, proprietary DeciBio databases and tools, and years of consulting experience in the precision medicine market, this report provides a quantitative and qualitative assessment of the key LBx clinical markets (e.g., early cancer detection, therapy selection, and MRD / monitoring) and the LBx pharma clinical trial and translational research market.  Qualitatively, we assess key market players,assays, and technologies, as well as the market drivers, moderators, and trends.  We also provide quotes from our interview campaign to illustrate a diversity of perspectives.  Quantitatively, we provide a 5-year (2022 –2027) market forecast segmented by application (early cancer detection, therapy selection, MRD, monitoring / surveillance, pharma research), geography (U.S.,Europe, APAC, ROW), tumor type (lung cancer, breast cancer, colorectal cancer, others), business model (kits vs. services), and, at a high-level, competitor.

The LBx market is evolving extremely quickly, and there is much development and strategy that happens outside of the public domain.  The assessments and projections made in this report are based only off information that is available in the public domain through Sep. 2022, as well as gathered from primary market research.

‍

Table of Contents

• Introduction & Methodology
• Executive Summary
• Therapy Selection
• MRD / Monitoring
• Early Cancer Detection
• Biopharma Trials & Research
• Company Profiles
• Appendix

‍

2^nd Edition: This version of the LBx report has been updated to account for recent developments and the expanding applications and complexity of the LBx space.

Updated Content

• Incorporated the latest trends in the LBx market, based on interviews with experts and secondary research
• Assessed new / current offerings and expected future portfolio developments
• Provided verbatim quotes from primary research to illustrate a variety of viewpoints and experiences
• Updated our database of LBx companies and their offerings, evaluated the latest performance data from key players
• Updated market sizing, segmentation, and forecast
• Evaluated emerging, high-growth applications in depth, elucidating both quantitative and qualitative market divers, moderators, and trends: (Minimal residual disease / monitoring, Early cancer detection)
• Developed deep-dive profiles of select key competitors

‍

Updated Market Numbers

• Developed four new market models to estimate the different segments of the LBx market; triangulated the market estimates against publicly available data (e.g., from SEC filings)
• Informed model assumptions with primary and secondary research, as well as DeciBio domain expertise
• Assessed market sizes for each of the market segments analyzed, including:
• Customer type (clinical, pharma)
• Indication
• Application
• Competitor
• Geography
• Projected revenues for each market segment from current year (2022) through 2027

‍

Report Scope

Technologies and Revenues Included:

• Liquid biopsies, in which a bodily fluid, primarily blood, is taken to detect molecular biomarkers
• Any soluble analyte (e.g., cfDNA, cfRNA, CTCs, exosomes, methylation)
• LBx testing done in routine clinical care and as part of biopharma trials and translational research
• Oncology-focused applications including cancer early detection (EDx), therapy (Tx) selection, and minimum residual disease (MRD) / monitoring
• Kits / reagents (e.g., off the shelf assays and LBx library prep) used in the testing of blood-based oncology biomarkers; the revenue captured is there venue to the kit manufacturer
• Send-out services in which a sample is sent to a centralized testing location; the revenue captured is the revenue to the service provider

Technologies and Revenues Excluded:

• Germline testing, prognostic testing, or any other kind of testing performed on analytes extracted from peripheral blood cells
• Academic trials and research (i.e., non-industry sponsored)
• Applications outside of oncology such as organ transplant, reproductive health, prenatal screening, routine bloodwork
• Sequencing reagents used to perform the assay
• Instruments and platforms used to run / analyze LBx samples (e.g., NGS, PCR machines)
• Software or bioinformatics support used in the analysis of LBx assays
• CDx licensing and development deals revenue, even if the licensing / deal involved LBx

‍

‍